Abstract
Several lines of evidence support a role of oxidative stress in the pathology of Alzheimer’s disease (AD). NAD(P)H:quinone oxidoreductase 1 (NQO1) catalyzes the two-electron reduction of quinones, preventing their participation in redox cycling and subsequent generation of reactive oxygen species. We examined association between the NQO1 C609T gene polymorphism and sporadic AD in a Chinese population comprising 311 AD patients and 330 controls. Our results showed a higher T-allele frequency in the AD cases compared with the controls. The difference was close to but did not reach statistically significant level [p = 0.059; odds ratio (OR) T versus C = 1.236; 95% confidence interval (95% CI), 0.992–1.540]. A significantly low C/C genotype frequency in the AD cases compared with the controls was detected (p = 0.025; OR C/C versus C/T + T/T = 0.674; 95% CI, 1.049–2.098) and APOE ε4 status analysis revealed significant difference in the APOE ε4 non-carriers (p = 0.036; OR = 0.633; 95% CI, 1.027–2.427). In the ≥65 years samples, significantly low C/C frequency in the AD cases in comparison with the controls was observed in the APOE ε4 non-carriers (p = 0.045; OR = 0.595; 95% CI, 1.010–2.794). These results indicated that the C/C genotype had a possible protective effect against AD development, and the T allele might be a weak risk factor for late onset AD.
Similar content being viewed by others
References
Braak, H., & Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica (Berl), 82, 239–259.
Butterfield, D. A., Hensley, K., Hall, N., et al. (1996). b-Amyloid-derived free radical oxidation: A fundamental process in Alzheimer’s disease. In W. Wasco, & R. E. Tanzi (Eds.) Molecular Models of Dementia (pp. 145–167). Totowa, NJ, USA: Humana.
Chesis, P. L., Levin, D. E., Smith, M. T., Ernster, L., & Ames, B. N. (1984). Mutagenicity of quinones: Pathways of metabolic activation and detoxification. Proceedings of the National Academy of Sciences of the United States of America, 81, 1696–1700.
Clairmont, A., Sies, H., Ramachandran, S., et al. (1990). Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: Use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci. Carcinogenesis, 20, 1235–1240.
Combarros, O., Infante, J., Llorca, J., & Berciano, J. (2004). Polymorphism at codon 66 of the brain-derived neurotrophic factor gene is not associated with sporadic Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders, 18, 55–58.
Ernster, L. (1967). DT-diaphorase. Methods in Enzymology, 10, 309–317.
Ernster, L., & Navazio, F. (1958). Soluble diaphorase in animal tissues. Acta Chemica Scandinavica, 2, 595–602.
Gatz, M., Pedersen, N. L., Berg, S., et al. (1997). Heritability for Alzheimer’s disease: The study of dementia in Swedish twins. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 52, M117–125.
Goto, Y., Hamajima, N., Honda, H., et al. (2005). Association between Helicobacter pylori seropositivity and NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism observed in outpatients and health checkup examinees. Gastric Cancer, 8, 12–17.
Huggins, C. B., Ueda, N., & Russo, A. (1978). Azo dyes prevent hydrocarbon-induced leukemia in the rat. Proceedings of the National Academy of Sciences of the United States of America, 75, 4524–4527.
Infante-Rivard, C., Vermunt, J. K., & Weinberg, C. R. (2007). Excess transmission of the NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism in families of children with acute lymphoblastic leukemia. American Journal of Epidemiology, 165, 1248–1254.
Kuehl, B. L., Paterson, J. W., Peacock, J. W., Paterson, M. C., & Rauth, A. M. (1995). Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. British Journal of Cancer, 72, 555–561.
Lafuente, M. J., Casterad, X., Trias, M., et al. (2000). NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis, 21, 1813–1819.
Lambert, M. P., Barlow, A. K., Chromy, B. A., et al. (1998). Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proceedings of the National Academy of Sciences of the United States of America, 95, 6448–6453.
Larson, R. A., Wang, Y., Banerjee, M., et al. (1999). Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood, 94, 803–807.
Lewis, S. J., Cherry, N. M., Niven, R. M., Barber, P. V., & Povey, A. C. (2001). Polymorphisms in the NAD(P)H:quinone oxidoreductase gene and small cell lung cancer risk in a UK population. Lung Cancer, 34, 177–183.
Ma, Q. L., Yang, J. F., Shao, M., Dong, X. M., & Chen, B. (2003). Association between NAD(P)H:quinone oxidoreductase and apolipoprotein E gene polymorphisms in Alzheimer’s disease. Zhonghua Yi Xue Za Zhi, 83, 2124–2127 (in Chinese).
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 34, 939–944.
Moran, J. L., Siegel, D., & Roses, D. (1999). A potential mechanism underlying the in creased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proceedings of the National Academy of Sciences of the United States of America, 96, 8150–8155.
Pike, C. J., Burdick, D., Walencewicz, A. J., Glabe, C. G., & Cotman, C. W. (1993). Neurodegeneration induced by beta-amyloid peptides in vitro: The role of peptide assembly state. Journal of Neuroscience, 13, 1676–1687.
Raina, A. K., Templeton, D. J., Deak, J. C., Perry, G., & Smith, M. A. (1999). Quinone reductase NQO1, a sensitive redox indicator, is increased in Alzheimer’s disease. Redox Report, 4, 23–27.
Rauth, A. M., Goldberg, Z., & Misra, V. (1997). DT-diaphorase: Possible roles in cancer chemotherapy and carcinogenesis. Oncology Research, 9, 339–349.
SantaCruz, K. S., Yazlovitskaya, E., Collins, J., Johnson, J., & DeCarli, C. (2004). Regional NAD(P)H:quinone noxidoreductase activity in Alzheimer’s disease. Neurobiology of Aging, 5, 63–69.
Schulz, W. A., Krummeck, A., Rosinger, I., et al. (1997). Increased frequency of a null-allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics, 7, 235–239.
Smith, M. T. (1999). Benzene, NQO1, and genetic susceptibility to cancer. Proceedings of the National Academy of Sciences of the United States of America, 96, 7624–7626.
Stanulla, M., Dynybil, C., Bartels, D. B., Dördelmann, M., et al. (2007). The NQO1 C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia: A matched-pair analysis from the ALL-BFM study group. Haematologica, 92, 1581–1582.
Strittmatter, W. J., & Roses, A. D. (1995). Apolipoprotein E and Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America, 92, 4725–4727.
Terry, R. D. (1994). Neuropathological changes in Alzheimer disease. Progress in Brain Research, 101, 383–390.
Traver, R. D., Siegel, D., Beall, H. D., et al. (1997). Characterization of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase). British Journal of Cancer, 75, 69–75.
Wang, B. B., Jin, F., Xie, Y. C., et al. (2006). Association analysis of NAD(P)H:quinone oxidoreductase gene 609 C/T polymorphism with Alzheimer’s disease. Neuroscience Letters, 409, 179–181.
Wang, Y., Santa-Cruz, K., DeCarli, C., & Johnson, J. A. (2000). NAD(P)H:quinone oxidoreductase activity is increased in hippocampal pyramidal neurons of patients with Aalzheimer’s disease. Neurobiology of Aging, 21, 525–531.
Wenham, P. R., Price, W. H., & Blandell, G. (1991). Apolipoprotein E genotyping by one-stage PCR. Lancet, 337, 1158–1159.
Wiemels, J. L., Pagnamenta, A., Taylor, G. M., Eden, O. B., Alexander, F. E., & Greaves, M. F. (1999). A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. Cancer Research, 59, 4095–4099.
Yankner, B. A., & Mesulam, M. M. (1991). Seminars in medicine of the Beth Israel Hospital, Boston. Beta-amyloid and the pathogenesis of Alzheimer’s disease. New England Journal of Medicine, 25, 1849–1857.
Acknowledgments
This work was supported by National Basic Research Program of China (no. 2007CB946902) and China Medical Board of New York (no. 99-699).
Author information
Authors and Affiliations
Corresponding author
Additional information
J-T Bian and H-L Zhao contributed equally to the work.
Rights and permissions
About this article
Cite this article
Bian, JT., Zhao, HL., Zhang, ZX. et al. Association of NAD(P)H:Quinone Oxidoreductase 1 Polymorphism and Alzheimer’s Disease in Chinese. J Mol Neurosci 34, 235–240 (2008). https://doi.org/10.1007/s12031-008-9036-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-008-9036-z